CDKN2A and astrocytoma (excluding glioblastoma): Although this analysis included both astrocytomas and oligodendrogliomas, the authors noted that of the three studies reporting 1p/19q co-deletions, when the co-deletion was excluded, CDKN2A retained its prognostic value [8].